BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells $14,225.60 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 523 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $27.20, for a total transaction of $14,225.60. Following the transaction, the executive vice president now owns 283,919 shares of the company’s stock, valued at approximately $7,722,596.80. The trade was a 0.18 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

BioLife Solutions Stock Performance

NASDAQ BLFS opened at $27.47 on Monday. The company has a fifty day simple moving average of $24.23 and a 200 day simple moving average of $23.24. BioLife Solutions, Inc. has a 12-month low of $11.91 and a 12-month high of $28.88. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The company has a market cap of $1.27 billion, a P/E ratio of -25.92 and a beta of 1.88.

Analyst Upgrades and Downgrades

Several research firms have issued reports on BLFS. TD Cowen raised their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. HC Wainwright reduced their price objective on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Craig Hallum raised their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, Northland Securities raised their price objective on shares of BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.50.

Institutional Trading of BioLife Solutions

Several hedge funds have recently bought and sold shares of BLFS. Vanguard Group Inc. boosted its holdings in BioLife Solutions by 11.5% during the 1st quarter. Vanguard Group Inc. now owns 2,868,335 shares of the medical equipment provider’s stock worth $53,208,000 after acquiring an additional 296,727 shares during the last quarter. Fred Alger Management LLC boosted its holdings in BioLife Solutions by 6.0% during the 2nd quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock worth $33,841,000 after acquiring an additional 88,840 shares during the last quarter. State Street Corp boosted its holdings in BioLife Solutions by 7.3% during the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after acquiring an additional 95,788 shares during the last quarter. Geode Capital Management LLC boosted its holdings in BioLife Solutions by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock worth $21,107,000 after acquiring an additional 18,473 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in BioLife Solutions by 9.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 794,971 shares of the medical equipment provider’s stock worth $17,034,000 after acquiring an additional 66,422 shares during the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.